Krystal Biotech (KRYS) Amortizatization of Intangibles (2019 - 2026)
Krystal Biotech's (KRYS) quarterly Amortizatization of Intangibles came in at $204000.0 in Q1 2026, down 8.93% year-on-year from $224000.0 in Q1 2025, and up 2.0% quarter-over-quarter from $200000.0 in Q4 2025.
Krystal Biotech (KRYS) Amortizatization of Intangibles (2019 - 2026) Analysis & Trends
Krystal Biotech has disclosed Amortizatization of Intangibles across 6 years of filings, most recently posting $204000.0 for Q1 2026.
- Amortizatization of Intangibles for Q1 2026 came in at $204000.0, down 8.93% year-over-year; the trailing twelve-month figure through Mar 2026 was $807000.0 (up 2.28% YoY), and the FY2025 annual result was $827000.0, up 10.71% from the prior year.
- Amortizatization of Intangibles came in at $204000.0 for Q1 2026 at Krystal Biotech, up from $200000.0 in the prior quarter.
- In the past five years, Amortizatization of Intangibles ranged from a high of $233000.0 in Q4 2023 to a low of $182000.0 in Q1 2024.
- The 4-year median for Amortizatization of Intangibles is $204000.0 (2026), against an average of $206307.7.
- Across the five-year window, Amortizatization of Intangibles retreated 18.26% in 2024 and rose 23.08% in 2025, its largest moves.
- Krystal Biotech's Amortizatization of Intangibles stood at $233000.0 in 2023, then declined by 18.03% to $191000.0 in 2024, then rose by 4.71% to $200000.0 in 2025, then advanced by 2.0% to $204000.0 in 2026.
- The last three Amortizatization of Intangibles figures came in at $204000.0 (Q1 2026), $200000.0 (Q4 2025), and $209000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 13,267.00 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Krystal Biotech | 10.23 Bn | 9.41 Bn | 110.03 Mn | 204,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 204,000.00 |
| Mar 31, 2026 | 204,000.00 |
| Dec 31, 2025 | 200,000.00 |
| Dec 31, 2025 | 200,000.00 |
| Sep 30, 2025 | 209,000.00 |
| Sep 30, 2025 | 209,000.00 |
| Jun 30, 2025 | 194,000.00 |
| Jun 30, 2025 | 194,000.00 |
| Mar 31, 2025 | 224,000.00 |
| Mar 31, 2025 | 224,000.00 |
| Dec 31, 2024 | 191,000.00 |
| Dec 31, 2024 | 191,000.00 |
| Sep 30, 2024 | 188,000.00 |
| Sep 30, 2024 | 188,000.00 |
| Jun 30, 2024 | 186,000.00 |
| Jun 30, 2024 | 186,000.00 |
| Mar 31, 2024 | 182,000.00 |
| Mar 31, 2024 | 182,000.00 |
| Dec 31, 2023 | 233,000.00 |
| Dec 31, 2023 | 233,000.00 |